CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The large number of people with TRD has driven very high sales expectations for Spravato, with some analysts suggesting sales could reach around $2.3 billion within five years of launch.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...